Epidemiology and biology of *BRAF*-*V600* mutant melanoma {#section1-1758835920925219}
=========================================================

Malignant melanoma is one of the most lethal types of skin cancer with a dramatic increase of its incidence in the last 50 years.^[@bibr1-1758835920925219]^ In a case study of patients diagnosed with melanoma between 2009 and 2015, only one in four patients (25%) with metastatic disease was still alive after 5 years from diagnosis.^[@bibr2-1758835920925219]^ Recent update from two clinical trials of metastatic melanoma patients treated with first-line immunotherapy, KEYNOTE-006 and Checkmate-067, have shown a 5-year survival of 38% and 52%, respectively.^[@bibr3-1758835920925219],[@bibr4-1758835920925219]^ Approximately 50% of patients with cutaneous melanoma have mutations in *BRAF*, a proto-oncogene belonging to the RAF family of serine/threonine protein kinases.^[@bibr5-1758835920925219]^ Activating mutations in BRAF kinase is involved in mitogen-activated protein kinase (MAPK) pathways, linking extracellular signals to intracellular processes such as growth, differentiation, proliferation, migration and apoptosis.^[@bibr6-1758835920925219]^ The most common mutation in the *BRAF* gene in melanoma is localized in exon 15 -- codon 600 -- of the *BRAF* gene, with a substitution of amino acid glutamic acid for valine at position 600 (V600E), accounting for 70--88% of all *BRAF* mutations. The second most common mutation accounting for 10--20% of all *BRAF* mutations is *V600K*. Less frequent mutations are *V600R, V600D* and *V600M*, comprising 2--5%, 1--4% and \<1% of all *BRAF* mutations, respectively.^[@bibr7-1758835920925219]^ These mutations seem to confer the same sensitivity to drugs of the *V600E* and *V600K* mutations, but to date clinical data on them are not significative.^[@bibr8-1758835920925219][@bibr9-1758835920925219]--[@bibr10-1758835920925219]^ Non-*V600* BRAF mutations such as L597P/Q/R/S and K601E, occurring in less than 5% of all melanoma patients, have also been described, even if, at the moment, more data are needed to elucidate their predictive and prognostic role.^[@bibr11-1758835920925219]^ *V600* mutations involve the kinase domain of the serine/threonine protein kinase *BRAF*, with constitutive activation of the MAPK pathway leading to an uncontrolled cell proliferation and survival.^[@bibr12-1758835920925219]^ Differences in biological and clinical features have been demonstrated between *BRAF*-*V600E* and *V600K* melanomas. In fact, comparison between *BRAF*-*V600E* and *V600K* cutaneous melanoma samples from the Cancer Genome Atlas showed that energy-metabolism and protein-translation pathways were upregulated in *V600K* tumors compared with *V600E* tumors, while proapoptotic pathways were downregulated.^[@bibr13-1758835920925219]^ A higher degree of cumulative sun-induced damage has been observed in *V600K* melanoma rather than in *V600E* melanomas, as well as a higher mutational burden. In fact, *V600K* mutations increase with increasing age.^[@bibr14-1758835920925219],[@bibr15-1758835920925219]^ Moreover, metastatic melanoma patients harboring *BRAF*-*V600K* mutation showed a shorter disease-free interval from diagnosis of primary melanoma to the occurrence of first distant metastasis compared with *V600E* mutant melanomas, even if no difference in overall survival (OS) has been demonstrated between the two groups.^[@bibr14-1758835920925219]^

Targeting *BRAF*-*V600* mutation in melanoma treatment {#section2-1758835920925219}
======================================================

BRAF inhibitors {#section3-1758835920925219}
---------------

In the early 2000s, the discovery of *BRAF*-*V600* mutations' role in cutaneous melanoma pathogenesis led researchers to develop new drugs able to block members of the MAPK pathway.^[@bibr16-1758835920925219]^ The first targeted agent tested against *BRAF*-*V600* mutant melanoma patients, sorafenib, despite preclinical evidences of efficacy,^[@bibr17-1758835920925219]^ unfortunately failed to demonstrate any clinical activity, as it did not improve progression-free survival (PFS) in phase II--III clinical trials.^[@bibr18-1758835920925219],[@bibr19-1758835920925219]^ Subsequently, a more selective and potent BRAF inhibitor, vemurafenib, formerly known as PLX4032, showed antitumor activity in both preclinical models and the early clinical setting.^[@bibr20-1758835920925219],[@bibr21-1758835920925219]^ In fact, in the phase III BRIM-3 trial, 675 patients with *BRAF-V600* mutant unresectable or metastatic melanoma were randomly assigned to receive either vemurafenib, at a dose of 960 mg twice daily orally (p.o.) or dacarbazine by intravenous infusion (i.v.).^[@bibr22-1758835920925219]^ In the vemurafenib and in the dacarbazine groups, PFS was 5.3 months and 1.6 months with a response rate of 48% and 5%, respectively, leading to the approval of vemurafenib by Food and Drug Administration (FDA) and European Medicine Agency (EMA) in this clinical scenario. Common adverse events (AEs) in patients treated with vemurafenib were mainly cutaneous events such as erythematous rash, photosensitivity and cutaneous squamous cell carcinomas, but also non-cutaneous events such as arthralgia and fatigue. Shortly thereafter, another second-generation BRAF inhibitor, dabrafenib, was approved for treatment of *BRAF-V600* mutant unresectable or metastatic melanoma patients, based on the results of the phase III BREAK-3 trial.^[@bibr23-1758835920925219]^ Dabrafenib showed similar activity compared with vemurafenib, although with a different toxicity profile including fewer photosensitivity, less frequent cutaneous squamous cell carcinoma and stronger pyrexia. Although dabrafenib and vemurafenib showed a strong activity in *BRAF-V600* mutant metastatic melanoma patients, their efficacy is limited by adverse events and by the emergence of acquired resistance mechanisms. These observations led to the design and development of new therapeutic agents. Encorafenib, formerly known as LGX-818, is the newest second-generation BRAF inhibitor with a higher affinity to BRAF and extended binding time. In fact, it has a peculiar pharmacodynamic profile, with a dissociation half-life of 30 hours compared with 2 and 0.5 hours of dabrafenib and vemurafenib, respectively. This prolonged effect causes a longer inhibition of its target compared with the old generations of BRAF inhibitors with a decrease of off-target effects responsible for adverse events, such as cutaneous squamous cell carcinoma.^[@bibr24-1758835920925219],[@bibr25-1758835920925219]^ A phase I dose escalation and expansion study of single agent encorafenib in metastatic *BRAF*-*V600* mutant melanoma showed a good clinical profile with no significant toxicity. The most common related adverse events were hand-foot syndrome and alopecia; other toxicities included vomiting and myopathy.^[@bibr26-1758835920925219],[@bibr27-1758835920925219]^

Dual inhibition of BRAF and MEK {#section4-1758835920925219}
-------------------------------

In clinical setting, the use of BRAF inhibitors pointed out two different concerns: a limited efficacy, due to the rapid onset of acquired resistance mechanisms, and an increased incidence of cutaneous squamous cell carcinomas.^[@bibr28-1758835920925219][@bibr29-1758835920925219]--[@bibr30-1758835920925219]^ Acquired resistance to BRAF inhibitors could be caused by several mechanisms and how to overcome it has become a relevant clinical need.^[@bibr31-1758835920925219][@bibr32-1758835920925219]--[@bibr33-1758835920925219]^ Multiple mechanisms of resistance have been identified. In particular, preclinical studies showed a key role of MEK, a serine/threonine protein kinase activated by BRAF kinase that through phosphorylation of ERK kinase, the last effector of the MAPK pathway, is physiologically involved in proliferation, differentiation, motility and survival in response to extracellular stimuli.^[@bibr34-1758835920925219],[@bibr35-1758835920925219]^ ERK kinases accumulate in nucleus, dimerize and activate substrates such as SRC-1, c-Fos, c-Myc, and STAT3.^[@bibr36-1758835920925219]^ Even though MEK is mainly activated by BRAF, mechanisms of RAF-independent MEK activation have been described.^[@bibr37-1758835920925219],[@bibr38-1758835920925219]^

Paradoxical activation of MAPK signaling using BRAF inhibitors consists of heterodimerization between impaired BRAF mutant kinases and non-mutant RAF isoforms, resulting in downstream MAPK pathway activation. Paradoxical activation depends on the upstream activity from an increased receptor tyrosine kinase (RTK) signaling or as a result of activating RAS mutations, thus explaining the higher incidence of cutaneous squamous cell carcinoma observed with single-agent BRAF inhibitors.^[@bibr39-1758835920925219],[@bibr40-1758835920925219]^

The evidence that combined BRAF/MEK inhibition could delay the onset of resistance and avoid the paradoxical activation of the MAPK pathway provided the rationale for testing the association of BRAF and MEK inhibitors (trametinib, cobimetinib and binimetinib) in this clinical scenario.^[@bibr41-1758835920925219],[@bibr42-1758835920925219]^ Clinical trials investigating the combination of BRAF and MEK inhibitors in *BRAF*-*V600* mutant melanoma patients reported a prolongation in both PFS and OS compared with single agent BRAF inhibitor.^[@bibr43-1758835920925219][@bibr44-1758835920925219][@bibr45-1758835920925219][@bibr46-1758835920925219]--[@bibr47-1758835920925219]^ In particular, coBRIM, a phase III clinical trial evaluating the addition of cobimetinib (MEK inhibitor) to vemurafenib (BRAF inhibitor) in untreated *BRAF*-*V600* metastatic melanoma patients, demonstrated better PFS, 9.9 *versus* 6.2 months, and overall response rate (ORR), 67 *versus* 44%, for doublet *versus* single agent drug.^[@bibr43-1758835920925219]^ COMBI-d and COMBI-v are two phase III clinical trials evaluating the addition of trametinib (MEK inhibitor) to dabrafenib (BRAF inhibitor) in untreated *BRAF*-*V600E/K* metastatic melanoma patients. The two trials differed in the single agent arm, using dabrafenib in COMBI-d and vemurafenib in COMBI-v, respectively. However, a statistically significant improvement in OS was demonstrated in both trials.^[@bibr44-1758835920925219],[@bibr45-1758835920925219]^ Five-year analysis of pooled extended-survival data from COMBI-d and COMBI-v showed PFS and OS rates of 19% and 34%, respectively. Interestingly, a multivariate analysis highlighted a 5-year OS of 55% in patients with normal baseline lactate dehydrogenase (LDH) levels and less than three metastatic sites and, in addition, 71% of patients who achieved a complete response (CR) were alive after 5 years.^[@bibr46-1758835920925219]^

Recently, COLUMBUS, a two-part randomized phase III trial, evaluated the newest doublet encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) in untreated *BRAF*-*V600* mutant melanoma patients. In part 1, patients were randomly allocated to receive encorafenib 450 mg (p.o., once daily) plus binimetinib 45 mg (p.o., twice daily) or encorafenib 300 mg (p.o., once daily) or vemurafenib 960 mg (p.o., twice daily). This trial showed an improvement of PFS from 7 to 15 months and OS from 16.9 to 33.6 months in the combined treatment arm compared with single agent vemurafenib. Results of part 2, evaluating the effect of encorafenib plus binimetinib *versus* encorafenib alone, have not yet been published.^[@bibr47-1758835920925219]^ Interestingly, all above-mentioned clinical trials showed that double inhibition of BRAF and MEK results in better clinical outcomes and it is known to reduce adverse events affecting patients treated with BRAF inhibitors alone, such as cutaneous squamous cell carcinoma associated to vemurafenib and dabrafenib and hand-foot syndrome associated to dabrafenib and encorafenib.^[@bibr43-1758835920925219][@bibr44-1758835920925219][@bibr45-1758835920925219][@bibr46-1758835920925219]--[@bibr47-1758835920925219]^

Recent data showed that *BRAF*-*V600E* and *V600K* mutant melanoma patients have distinct molecular profiles. In particular, molecular pathway analysis showed that *BRAF*-*V600K* mutant melanomas have lower expression of ERK and higher expression of PI3K-AKT genes than V600E mutant melanoma and this could in part explain the lower sensitivity of *BRAF*-*V600K* mutant melanomas to double BRAF and MEK inhibition.^[@bibr15-1758835920925219]^ PI3K-AKT pathway signaling, however, seems to play a complex role in resistance to double BRAF and MEK inhibition, because it seems to favor the selection and expansion of resistant tumor subclones with MAPK-reactivating mutations rather than being a molecular driver of resistance itself.^[@bibr48-1758835920925219]^

Immunotherapy and *BRAF*-*V600* mutant melanoma {#section5-1758835920925219}
===============================================

The introduction of immune-checkpoint inhibitors (ICIs) has made the greatest impact in the management of melanoma treatment. Ipilimumab, a monoclonal antibody that activates the immune system by inhibiting CTLA-4 (cytotoxic T-lymphocyte associated protein 4), has been the first ICI to improve survival of advanced/metastatic melanoma patients.^[@bibr49-1758835920925219]^ Nivolumab and pembrolizumab, two monoclonal antibodies against PD-1 (programmed cell death protein 1), demonstrated better PFS and OS than ipilimumab, with a more favorable toxicity profile.^[@bibr50-1758835920925219],[@bibr51-1758835920925219]^ Nivolumab and ipilimumab combined treatment showed an increase in both PFS and OS, with a remarkable and significant increase in ORR, PFS and OS compared with ipilimumab as first-line treatment in patients without brain metastases, although at the cost of more grade 3--4 toxicities, which occurred in 59% of patients treated in the combination arm.^[@bibr4-1758835920925219],[@bibr52-1758835920925219]^

Data regarding the efficacy of ICIs in *BRAF-V600* mutant melanoma have been retrospectively extrapolated from subgroup analysis of the main phase III clinical trials which led to the approval of ipilimumab, pembrolizumab and nivolumab in advanced/metastatic melanoma patients and included different percentages of BRAF mutants. In particular, KEYNOTE-006 was an open-label, multicenter controlled, phase III clinical study evaluating the role of pembrolizumab (10 mg/kg) every 2 or 3 weeks *versus* four doses of ipilimumab (3 mg/kg) every 3 weeks in ipilimumab-naive histologically confirmed advanced melanoma patients with known *BRAF*-*V600* status and up to one previous systemic therapy. The estimated 6-month PFS rate was 47.3% for pembrolizumab arm every 2 weeks, 46.4% for pembrolizumab arm every 3 weeks and 26.5% for the ipilimumab arm. Interestingly, 36.2% of enrolled patients were *BRAF*-*V600* mutant and approximately 50% of them had received BRAF inhibitor treatment. Most patients pretreated with BRAF inhibitors had elevated baseline LDH levels or symptomatic and rapidly progressive disease at diagnosis. Furthermore, the hazard ratio (HR) for PFS for both untreated and previously treated *BRAF*-*V600* patients was in a range between 0.44 and 0.87 in favor of pembrolizumab (both 2 and 3-week schedules), while HR for OS was in a range between 0.67 and 0.84, with a not statistically significant benefit in OS for both pembrolizumab arms. However, it must be noted that patients were not stratified according to BRAF status in this clinical trial.^[@bibr51-1758835920925219]^ The 5-year update of the study showed a median OS of 20.4 months in *BRAF*-*V600* patients.^[@bibr4-1758835920925219]^

Although in the phase III clinical trial, CheckMate 066, evaluating the efficacy of nivolumab *versus* dacarbazine, no *BRAF*-*V600* mutant patients were enrolled,^[@bibr50-1758835920925219]^ efficacy data of nivolumab in *BRAF-V600* mutant patients can be extrapolated from CheckMate 067, a phase III clinical trial evaluating the activity of nivolumab in combination with ipilimumab *versus* nivolumab alone *versus* ipilimumab alone as first-line metastatic melanoma treatment.^[@bibr52-1758835920925219]^ In this trial, approximately 31% of patients were *BRAF*-*V600* mutant and the mutational status of BRAF was also a stratification factor for randomization. In the combination arm, PFS of *BRAF-V600* mutant and *BRAF* wild-type melanoma patients was similar, 11.7 and 11.2 months, respectively. However, a recent update of this clinical trial has shown that 5-year OS for patients with *BRAF-V600* mutant tumors reached 60% in the combination group, 46% in the nivolumab group and 30% in the ipilimumab group, whereas these results for *BRAF* wild-type patients were 48%, 43% and 25%, respectively.^[@bibr4-1758835920925219]^ In a descriptive comparison between treatments in *BRAF-V600* mutant patients, the combination treatment seemed to provide more benefit than nivolumab monotherapy, with a HR of 0.70 for OS.^[@bibr53-1758835920925219]^ In addition, a prespecified subgroup analysis revealed the possible predictive role of PD-L1 expression. In fact, median PFS was 14 months in patients with a positive PD-L1 tumor (defined as at least 5% of tumor cells showing PD-L1 staining) treated either with nivolumab or nivolumab plus ipilimumab, whereas median PFS in patients with a negative PD-L1 tumor was 5.3 and 11.2 months in the nivolumab and combination arm, respectively.^[@bibr52-1758835920925219]^

Although PD-L1 positive melanoma patients could potentially benefit more than PD-L1 negative patients from immune-based therapies,^[@bibr52-1758835920925219],[@bibr54-1758835920925219]^ anti-PD-1 antibodies are currently used regardless of PD-L1 expression status because efficacy data have been observed also in the PD-L1 negative population. Moreover, new biomarkers that could be used to differentiate between patients who will derive the most benefit from treatment are needed. Tumor mutational burden (TMB) is a measurement of the number of mutations carried by tumor cells, that has recently been used to predict a favorable outcome to PD-1/PD-L1 blockade across different metastatic tumors, including melanoma.^[@bibr55-1758835920925219]^ A retrospective study evaluating TMB differences in *BRAF*-*V600* mutant *versus BRAF* wild-type melanomas showed a significant difference in TMB between these two groups.^[@bibr56-1758835920925219],[@bibr57-1758835920925219]^ However, the impact of TMB as a biomarker of response to immunotherapy in *BRAF-V600* mutant melanoma patients remains unknown.

Prognostic and clinical factors in *BRAF-V600* mutant melanoma for optimal treatment strategies {#section6-1758835920925219}
===============================================================================================

Currently, we do not yet have results of ongoing clinical trials comparing targeted therapy and immunotherapy in first-line treatment *BRAF*-*V600* mutant metastatic melanoma patients. For naive *BRAF-V600* mutant melanoma patients, the choice between these two treatments should be made by considering different aspects such as prognostic factors, the different mechanism of action of therapeutic agents used and the inter-tumor variability among melanoma patients. Prognostic factors that have been studied until now in *BRAF-V600* mutant melanoma patients include serum LDH, site/number of metastasis and clinical factors (Eastern Cooperative Oncology Group performance status \[ECOG PS\]) ([Table 1](#table1-1758835920925219){ref-type="table"}).^[@bibr58-1758835920925219][@bibr59-1758835920925219][@bibr60-1758835920925219]--[@bibr61-1758835920925219]^ Other prognostic factors are currently under investigation.

###### 

Prognostic and clinical factors and their influence on therapeutic response in metastatic melanoma patients.

![](10.1177_1758835920925219-table1)

  Prognostic factor               Value      Immunotherapy[\*](#table-fn2-1758835920925219){ref-type="table-fn"}^[@bibr58-1758835920925219],[@bibr59-1758835920925219]^   BRAF + MEK inhibitors^[@bibr60-1758835920925219],[@bibr61-1758835920925219]^
  ------------------------------- ---------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------
  LDH                             Normal     1-year OS: 72%                                                                                                               2-year PFS: 39--40%
                                  \>ULN      1-year OS: 44%                                                                                                               2-year PFS: 14%
                                  \>2× ULN                                                                                                                                2-year PFS: 6%
                                                                                                                                                                          3-year PFS: 0%
  Sum of lesion diameters (SLD)   ≤44 mm                                                                                                                                  3-year PFS: 52%
                                  \>44 mm                                                                                                                                 3-year PFS: 0%
                                  \<66 mm                                                                                                                                 3-year PFS: 43%
                                  ≥66 mm                                                                                                                                  3-year PFS: 27%
                                  102 mm     ORR: 42%                                                                                                                     
                                  ≥102 mm    ORR: 24%                                                                                                                     

ULN, upper limit of normal; OS, overall survival; PFS, progression-free survival; ORR, overall response rate.

Immunotherapy data include both *BRAF* wild-type and *V600*-mutant patients.

LDH {#section7-1758835920925219}
---

Elevated serum LDH is one of the strongest independent prognostic factors in metastatic melanoma patients, regardless of the number and site of metastases.^[@bibr62-1758835920925219],[@bibr63-1758835920925219]^ LDH is not just a secreted enzyme. In fact, its elevated serum levels reflect the switch to a glycolytic phenotype in hypoxic conditions by melanoma cells.^[@bibr63-1758835920925219]^ The evidence of the prognostic role of LDH in metastatic melanoma patients had led researchers to include its levels in the penultimate American Joint Committee on Cancer (AJCC) melanoma staging system edition (VII edition, 2009). In fact, patients with elevated LDH levels were assigned to M1c category regardless of distant metastatic sites. Recently, in the ultimate AJCC melanoma staging system (VIII edition, 2018), levels of LDH are no longer used as a stratification criterion for assigning patients to M1 subgroups, even if each subgroup has the number (0) or (1) to indicate normal or elevated LDH, respectively.^[@bibr64-1758835920925219]^

The role of baseline LDH levels as a prognostic marker has been evaluated in patients with advanced/metastatic melanoma treated with nivolumab and pembrolizumab in a single institution trial. Patients with an elevated baseline LDH level had a significantly shorter OS compared with patients with a normal baseline LDH level and, interestingly, a change in LDH levels during treatment was predictive of response and OS. However, in this retrospective analysis, there was no selection criterion for the line of treatment and the number of *BRAF-V600* mutant patients was not balanced between the two groups.^[@bibr58-1758835920925219]^

A recent pooled analysis of four randomized clinical trials including *BRAF-V600* mutant metastatic melanoma patients treated with vemurafenib ± cobimetinib showed clearly the influence on PFS by baseline LDH level. In fact, in patients treated with doublet therapy, 2-year PFS decreased dramatically from 40% for normal baseline LDH levels to less than 6% for baseline LDH \> 2× upper limit of normal (ULN).^[@bibr60-1758835920925219]^ A second pooled analysis of two-phase III clinical trials in *BRAF*-*V600* mutant metastatic melanoma patients treated with dabrafenib and trametinib showed similar results, with 2-year PFS of 39% for normal baseline LDH levels compared with 14% for elevated baseline LDH levels,^[@bibr61-1758835920925219]^ confirming the results of a previous pooled analysis of a pivotal phase II and two phase III trials with the same drugs.^[@bibr65-1758835920925219]^ Noteworthy, in both vemurafenib plus cobimetinib and dabrafenib plus trametinib pooled analysis, 3-year PFS in patients with baseline LDH \> 2× ULN was 0%.^[@bibr60-1758835920925219],[@bibr61-1758835920925219]^

Site, number and size of metastases {#section8-1758835920925219}
-----------------------------------

Melanoma cells could spread through lymphatic or hematic circulation, affecting subcutaneous tissues and regional/distant lymph nodes or vital organs such as lungs, liver and/or brain.^[@bibr66-1758835920925219]^ Sites of metastases have been pointed out as strong prognostic factors in melanoma patients. In particular, central nervous system (CNS) invasion represented the worst prognostic factor, with median OS for patients with brain metastasis of 17--22 weeks.^[@bibr67-1758835920925219]^ The VII edition the AJCC melanoma staging system divided stage IV into three different prognostic categories based on metastatic sites and LDH levels: M1a included patients with distant metastasis in the skin, subcutaneous tissue, or distant lymph nodes and a normal LDH level (good prognosis); M1b included patients with lung metastasis and a normal LDH level (intermediate prognosis); and, finally, M1c patients with other visceral metastatic sites or with elevated LDH level independently from metastatic sites (poor prognosis).^[@bibr68-1758835920925219]^ The VIII edition the AJCC melanoma staging system revised M classification. In fact, elevated LDH does not identify a specific subgroup and a new category, M1d, identifies patients with CNS metastases (irrespective of the presence of metastatic disease at other sites).^[@bibr64-1758835920925219]^

In addition, baseline disease burden has been shown to be associated with therapeutic responses and outcomes across multiple cancer types, including metastatic melanoma.^[@bibr68-1758835920925219]^ Although tumor burden can be measured and reported in different ways, patients who have smaller and fewer metastases have improved clinical and pathological responses and survival compared with patients with greater baseline tumor burden.^[@bibr68-1758835920925219]^ A pooled analysis of 581 patients treated with pembrolizumab and with measurable disease showed that patients with baseline tumor size less than the median (10.2 cm) had an ORR of 42%, whereas patients with tumor burden at or above the median had an ORR of 24%.^[@bibr59-1758835920925219]^ The role of tumor burden as a negative prognostic biomarker has been evaluated in a pooled analysis of advanced/metastatic melanoma patients treated with BRAF and MEK inhibitors. The analysis showed that metastatic burden has a negative effect on PFS. In particular, when ECOG PS is 0 and baseline LDH level is \<2× ULN, patients treated with vemurafenib plus cobimetinib had a 3-year PFS of 51.8% and 0% if baseline sum of lesion diameters (SLD) was ≤44 mm or \>44 mm, respectively.^[@bibr60-1758835920925219]^ In the case of normal baseline LDH level, in patients treated with dabrafenib plus trametinib the 3-year PFS was 43% and 27% if SLD was \<66 mm or ≥66 mm, respectively.^[@bibr61-1758835920925219]^

Clinical factors {#section9-1758835920925219}
----------------

Performance status (PS) deterioration due to rapid growth of metastases is not uncommon in melanoma patients, especially in *BRAF*-*V600* mutant patients. In first-line metastatic melanoma phase III trials, patients with ECOG PS ⩾1 were represented within a variable range of 26--35%.^[@bibr43-1758835920925219][@bibr44-1758835920925219][@bibr45-1758835920925219][@bibr46-1758835920925219]--[@bibr47-1758835920925219],[@bibr50-1758835920925219][@bibr51-1758835920925219]--[@bibr52-1758835920925219]^ Pooled analysis showed that baseline PS could play a key role for survival outcome in *BRAF-V600* mutant metastatic melanoma patients treated with BRAF and/or MEK inhibitors. In fact, in the good prognosis patients' group (LDH ⩽ 2× ULN), the subgroup with ECOG PS = 0 had a 1-year PFS of 47% whereas patients with ECOG PS = 1 had a 1-year PFS of 11%.^[@bibr60-1758835920925219]^ Moreover, in metastatic melanoma patients treated with dabrafenib plus trametinib as first-line therapy, PFS is strongly affected by performance status, with a HR between PS 0 and PS ⩾ 1 of 0.585 (*p* \< 0.0001). A meta-analysis of 18 randomized trials was performed to investigate the predictive role of PS towards treatment with ICIs. The treatment with checkpoint inhibitors improves survival regardless of patients' PS. In particular, four clinical trials including advanced melanoma patients were incorporated in this meta-analysis and demonstrated that patients with ECOG PS = 1 benefited from immunotherapy (HR 0.82, range: 0.72--0.93).^[@bibr69-1758835920925219]^ However, most patients with poor performance status (PS ⩾ 2) have been excluded from pivotal phase III immunotherapy trials.^[@bibr70-1758835920925219]^

New prognostic and predictive factors {#section10-1758835920925219}
-------------------------------------

Analysis of circulating tumor DNA (ctDNA) is a non-invasive method that could be used for many clinical purposes, from early detection of cancer to monitoring anti-cancer treatment efficacy.^[@bibr71-1758835920925219]^ Tumor DNA can be released by cancer cells either through a passive mechanism by apoptotic and necrotic cancer cells and/or through active mechanism of spontaneous release of DNA fragments into the circulation.^[@bibr72-1758835920925219]^ Detection and quantification of ctDNA is mostly performed with digital polymerase chain reaction (dPCR) and next generation sequencing (NGS). To assess whether ctDNA levels could be used as an early indicator of changes in tumor burden in melanoma patients with advanced disease and treated with checkpoints inhibitors, plasma samples have been collected serially from 12 patients. Levels of ctDNA correlated with clinical and radiological outcomes.^[@bibr73-1758835920925219]^ Moreover, basal ctDNA levels could predict response to treatment in naive metastatic melanoma patients. In fact, in a cohort of 48 Australian subjects, 35 of them had detectable ctDNA in the plasma at baseline, and lower levels were significantly associated with response to treatment and prolonged PFS, regardless of the therapeutic approach adopted. In addition, ctDNA levels were shown to predict resistance to treatment earlier than radiological detection of progressive disease.^[@bibr74-1758835920925219]^ To investigate the possible role of ctDNA levels as prognostic biomarker in *BRAF*-*V600* mutant advanced melanoma a retrospective analysis of four clinical trials (BREAK-2, BREAK-3, BREAK-MB and METRIC) has been performed. In particular, *BRAF* ctDNA mutations were detectable in 76% and 81% of patients harboring *BRAF*-*V600E* and *V600K* mutations, respectively. However, *BRAF*-*V600E* and *V600K* mutant positive tissue patients that were negative for *BRAF* ctDNA mutations in plasma had longer PFS and OS compared with patients with detectable *BRAF* ctDNA mutations, suggesting the role of *BRAF-V600* mutant ctDNA as an independent prognostic factor for PFS.^[@bibr75-1758835920925219]^ Waiting for further studies to validate these interesting results, ctDNA is now in the spotlight as a new feasible prognostic marker in *BRAF-V600* mutant metastatic melanoma. However, how these results will change the treatment paradigm is still unknown.

Recently, gene expression signatures have been proposed as a prognostic and/or predictive tool in cancer treatment.^[@bibr76-1758835920925219]^ Over the past 10 years, *BRAF* mutation-associated gene expression signature has been identified including different genes involved in melanoma immune response such as MAGE-D2, CD63 and HSP70.^[@bibr77-1758835920925219],[@bibr78-1758835920925219]^ These immune gene expression signatures could be useful to characterize tumor immunity for predicting response to immunotherapy. Recently, interferon gamma (IFN-γ) signature has been evaluated as a marker of response to immunotherapy with significant results in terms of prediction of response in both non-small cell lung cancer and melanoma.^[@bibr79-1758835920925219]^ Interestingly, in patients with resected *BRAF-V600* mutant stage III melanoma from the COMBI-AD trial (combination of dabrafenib and trametinib *versus* placebo as adjuvant treatment), IFN-γ signature played a crucial role as a prognostic factor in both arms, identifying patients with longer relapse-free survival (RFS) independently of TMB status.^[@bibr80-1758835920925219],[@bibr81-1758835920925219]^ Thus, IFN-γ signature could be a potential prognostic and predictive factor in *BRAF*-*V600* mutant melanoma. However, gene expression signature could not be used in clinical practice yet due to paucity of data.

Treatment of brain metastases in *BRAF*-*V600* mutant melanoma {#section11-1758835920925219}
==============================================================

Melanoma is one of the malignant tumors with the highest probability to develop brain metastases.^[@bibr82-1758835920925219]^ Concerning *BRAF*-*V600* mutant melanoma, genetic concordance between paired tissue samples from primary tumors and brain metastases is variable from 80--100%, with cases of *BRAF*-*V600* positive brain metastases and paired negative melanoma primaries.^[@bibr83-1758835920925219],[@bibr84-1758835920925219]^ Different strategies could be used against melanoma brain metastases such as surgery (metastasectomy), radiotherapy (stereotactic radiosurgery: SRS), medical therapy (immunotherapy, targeted therapy) and/or combinations of them. The number, size, localization and symptoms should guide clinicians to choose the right approach for every single patient with melanoma brain metastases.

Targeted therapy {#section12-1758835920925219}
----------------

Preclinical studies have demonstrated that concentrations of targeted drugs such as vemurafenib, dabrafenib and trametinib in the brain of murine models without CNS metastases were very low.^[@bibr82-1758835920925219]^ However, it should be assumed that the presence of brain metastases (\>0.25 mm²) alters the blood--brain barrier (BBB), allowing penetration of these drugs in metastatic sites.^[@bibr85-1758835920925219]^ Dabrafenib and vemurafenib monotherapy showed variable intracranial ORR ranging from 15--35%, with lower responses in *BRAF*-*V600K* mutant patients.^[@bibr86-1758835920925219],[@bibr87-1758835920925219]^

COMBI-MB was a phase II clinical trial evaluating the role of dabrafenib plus trametinib in *BRAF*-*V600* mutant melanoma patients with brain metastases. Patients were divided into four cohorts: cohort A including patients harboring *BRAF-V600E* mutation, with asymptomatic brain metastases, no previous local brain therapy and an ECOG PS of 0 or 1; cohort B including patients harboring *BRAF-V600E* mutation, with asymptomatic brain metastases, with previous local brain therapy and an ECOG PS of 0 or 1; cohort C including patients harboring *BRAF-V600D/K/R* mutations, asymptomatic brain metastases, with or without previous local brain therapy and an ECOG PS of 0 or 1; cohort D including patients harboring *BRAF-V600D/E/K/R* mutations, symptomatic brain metastases, with or without previous local brain therapy and an ECOG PS of 0, 1, or 2. Results of this trial showed that overall intracranial responses (complete and partial responses, CR + PR) were high (56--59%) in cohorts A, B and D, but not in cohort C (44%). Median PFS and OS were longer in cohort B. However, the small sample size and the non-randomized design limit the external validity of these results.^[@bibr88-1758835920925219]^

Immunotherapy {#section13-1758835920925219}
-------------

Even if in physiological condition BBB limits lymphocytes trafficking, mechanisms such as cytokines, cell adhesion molecules and matrix metalloproteinases could allow T cells to access the CNS parenchyma.^[@bibr82-1758835920925219]^ Clinical trials evaluating immunotherapy in melanoma patients often did not include those with CNS metastases, especially patients who were symptomatic and/or requiring steroids. Nevertheless, few data demonstrating the efficacy and safety of immunotherapy in melanoma patients with brain metastases are available. In particular, in a phase II clinical trial it has been shown that ipilimumab could prolong survival in asymptomatic patients with brain metastases, with a median OS of 7 months even if CNS objective responses, the primary endpoint of this trial, were 16% in asymptomatic patients and only 5% in symptomatic patients.^[@bibr89-1758835920925219]^ The combination of ipilimumab and nivolumab increased response rate in patients with untreated brain metastases from cutaneous melanoma, with a rate of intracranial clinical benefit of 57%, and reaching a CR rate of 26%, a partial response (PR) rate of 30% and a 81.5% estimated rate of OS at 12 months. In this trial, 57.4% of patients had *BRAF-V600* mutant metastatic melanoma and, interestingly, this patient subgroup had the higher objective response rate (57% *versus* 40% of *BRAF* wild-type).^[@bibr90-1758835920925219]^ The Anti-PD-1 Brain Collaboration trial evaluated the efficacy of nivolumab alone or in combination with ipilimumab in patients with active melanoma brain metastases, including *BRAF*-*V600* mutant tumors, either treated or untreated with BRAF and MEK inhibitors. The higher intracranial response rate (56%) was registered in the cohort of patients with asymptomatic melanoma brain metastases who had no previous local brain therapy and were treated with ipilimumab plus nivolumab. Notably, intracranial response, PFS and OS were low after progression on BRAF and MEK inhibitors, according to translational evidence of immune-resistance phenotype developing progression on BRAF inhibitor-based therapy.^[@bibr91-1758835920925219]^

Combination strategies {#section14-1758835920925219}
----------------------

Combining immunotherapy and targeted therapy for *BRAF*-*V600* mutant metastatic brain melanoma (MBM) patients could be a more effective treatment compared with single modalities. Ongoing clinical trials are evaluating this possibility.^[@bibr82-1758835920925219]^ Radiation therapy and immunotherapy combined strategy for MBM has never been investigated prospectively. Retrospective studies showed a significant improvement in OS in patients treated with ipilimumab and SRS (≈20 months).^[@bibr92-1758835920925219],[@bibr93-1758835920925219]^ Also, radiosurgery has been investigated retrospectively, with better outcomes observed in patients that started ICIs within 8 weeks after undergoing radiosurgery.^[@bibr94-1758835920925219]^ Targeted therapy in combination with radiotherapy is currently being investigated in ongoing clinical trials, but at the cost of potential increased toxicities (mostly dermatological, pulmonary and neurological) from the combination of BRAF inhibitors and radiotherapy.^[@bibr95-1758835920925219][@bibr96-1758835920925219][@bibr97-1758835920925219]--[@bibr98-1758835920925219]^

Current scenario and future direction in *BRAF*-*V600* mutant melanoma treatment {#section15-1758835920925219}
================================================================================

First-line and second-line therapy {#section16-1758835920925219}
----------------------------------

At present, we do not have any data from randomized trials regarding the best first-line treatment for *BRAF*-*V600* mutant metastatic melanoma patients. In fact, immunotherapy and targeted therapy could both be used as first-line treatment for these patients, even if prognostic and clinical factors suggest important differences between the two therapeutic approaches. The main differences between immunotherapy and targeted therapy are the following:

1.  1) Onset of clinical response, generally rapid for targeted therapy and slow for immunotherapy;

2.  2) Duration and deepness of response, generally longer and more durable with immunotherapy than targeted agents. On the other hand, a higher response rate is observed with targeted therapy even though resistance could develop in a relevant percentage of cases;

3.  3) Patterns of progression. In particular, clinical data showed that rapid disease progression and poor performance status after targeted therapies could significantly reduce the proportion of patients receiving immunotherapy as second-line treatment.^[@bibr99-1758835920925219]^

4.  4) Patients' medical history and comorbidities. ICIs should be avoided in patients with autoimmune diseases, especially if requiring high-dose corticosteroids or immunosuppressive drugs. Targeted therapies could worsen heart failure, arrhythmias or retinal pathologies. Risk--benefit ratio must be considered for each patient before starting any of these drugs.^[@bibr100-1758835920925219]^

In the absence of randomized trials comparing, head to head, the efficacy of immunotherapy *versus* targeted therapy, clinical and prognostic factors, such as baseline LDH, site and number of metastases and ECOG PS, should be addressed by clinicians in the treatment of *BRAF-V600* mutant melanoma patients.

Based on available data from phase III clinical trials and meta-analysis, some considerations are needed. In particular, in advanced melanoma patients with normal baseline LDH levels, targeted therapy should be preferred in the case of low metastatic burden or in the case of aggressive and/or symptomatic disease, even if a short-term involvement of vital organs is expected, whereas immunotherapy could be considered as first-line treatment in patients with high metastatic burden but slowly progressive and without symptoms, and also in the case of low metastatic burden in the light of long-term responses.^[@bibr60-1758835920925219],[@bibr61-1758835920925219]^ The combination of nivolumab and ipilimumab could be preferred to nivolumab single agent, especially in case of PD-L1 expression \<5% as discussed before, even if, regardless of PD-L1 expression, in *BRAF V600* patients the difference in 5-year OS between the combination and nivolumab is not statistically significant (HR 0.70, range 0.41--1.05)^[@bibr53-1758835920925219]^ and the rate of G3-4 AEs is more than doubled (59% *versus* 23%, respectively).^[@bibr4-1758835920925219],[@bibr52-1758835920925219]^ In the case of advanced melanoma patients with elevated baseline LDH levels even if PFS and OS data are in favor of first-line treatment with immunotherapy, the goal of rapid response in the case of symptomatic disease should suggest clinicians to use targeted therapy. For untreated patients with brain metastases, even in the absence of direct comparison, targeted therapy achieves better results than immunotherapy, especially in symptomatic patients, even if nivolumab plus ipilimumab could be a good option for asymptomatic patients as described before^[@bibr88-1758835920925219][@bibr89-1758835920925219]--[@bibr90-1758835920925219]^ ([Figure 1](#fig1-1758835920925219){ref-type="fig"}). Second-line treatment depends on which therapy that patient has previously received (immunotherapy after targeted therapy and *vice versa*).

![Proposed algorithm for first-line treatment choice in untreated *BRAF-V600* mutant metastatic melanoma patients.\
BRAFi, BRAF inhibitor; LDH, serum lactate dehydrogenase; MEKi, MEK inhibitor; SLD, sum of lesion diameters.](10.1177_1758835920925219-fig1){#fig1-1758835920925219}

Future of *BRAF-V600* mutant melanoma treatment {#section17-1758835920925219}
-----------------------------------------------

Several trials are evaluating the association between immunotherapy and targeted therapy as first-line treatment in *BRAF*-*V600* mutant melanoma patients (NCT02902042, NCT02908672, NCT02910700, NCT01940809). The rationale of combining immune and targeted therapy is to obtain maximal response rates and durable responses, with an acceptable safety profile. Results of the phase II KEYNOTE-022 trial, in which *BRAF-V600* metastatic melanoma patients were randomly assigned to receive pembrolizumab or placebo in addition to dabrafenib and trametinib as first-line treatment, have recently been published. PFS, the primary endpoint of this study, showed an increase from 10.3 months for the dabrafenib and trametinib combined treatment group to 16 months for the addition of pembrolizumab to the doublet treatment group. However, this improvement of PFS did not reach the planned benefit for a statistically significant improvement. Moreover, a higher incidence of grade 3--4 toxicities in the combination arm compared with doublet (58.3 *versus* 26.7%) has been described.^[@bibr101-1758835920925219]^ Despite these results, ongoing phase III clinical trials (NCT02908672, NCT02967692) will better elucidate the role of association between immunotherapy and targeted therapy in these patients.

Another strategy under investigation is to find the optimal sequence for BRAF mutant melanoma patients' treatment. Data from ongoing clinical trials, mainly NCT02224781, evaluating dabrafenib plus trametinib followed by nivolumab plus ipilimumab or *vice versa*, and NCT02631447, also known as SECOMBIT, are still immature, but they will definitely answer important clinical questions about the right treatment approach in *BRAF-V600* mutant patients. The phase II SECOMBIT trial, evaluating the best sequencing approach with the combination of encorafenib plus binimetinib and the combination of nivolumab plus ipilimumab, will also add interesting data about patients treated with an induction of targeted therapy followed immediately by immunotherapy and, in the case of progression, rechallenge with targeted therapy ('sandwich' strategy). A phase II clinical trial has evaluated the role of rechallenge treatment with BRAF and MEK inhibitors in *BRAF V600E/K* mutant patients who had previously progressed on first-line BRAF inhibitors (with or without MEK inhibitors) and who had progressed also on second-line to ICIs, with an interval between recruitment and the last administration of a BRAF inhibitor of more than 12 weeks.^[@bibr102-1758835920925219]^ An interesting disease control rate (DCR) of 72% was achieved, corroborating the use of BRAF and MEK inhibitors in this setting, but only data from future phase III clinical trials could clarify the role of rechallenge with these drugs.

Currently, data from clinical practice have not shown any difference in sequencing immune and targeted therapy,^[@bibr103-1758835920925219]^ but a simulation model developed to estimate the cost-effectiveness of treatment sequences in *BRAF-V600* mutant metastatic melanoma suggests that starting treatment with anti-PD-1 plus anti-CTLA-4 is more cost-effective than starting with anti-PD-1 monotherapy or targeted therapy.^[@bibr104-1758835920925219]^

Conclusion {#section18-1758835920925219}
==========

New therapies such as targeted agents and ICIs have changed outcomes of *BRAF*-*V600* mutant metastatic melanoma patients. These two classes of drugs have substantial differences regarding spectrum of activity, safety profiles and, nevertheless, costs. Currently, prognostic and clinical factors should guide the choice between ICIs and targeted therapies, waiting for the results of ongoing clinical trials evaluating which one could be the best upfront approach. The combination of immune and targeted therapies could represent a better choice, but probably not for all patients and, almost definitely, at the cost of more toxicities. The optimization of treatment strategies with current drugs, the validation of promising predictive factors and the discovery of new pharmacological agents will meaningfully improve, in the near future, the clinical management of these patients.
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